Kevin Crowley
Senior Managing Director, Investments at Connecticut Innovations
· New Haven, CT
Check size
Undisclosed
Lead stage
pre-seed
Deals tracked
13
Sectors
Bioscience, Life Sciences
Bioscience
Life Sciences
Healthcare
bioscience
early-stage innovation
pre-seed
seed
Series A
later stage
Connecticut
About Kevin
Kevin Crowley is an Executive Officer and Director with experience in institutional investment and corporate governance. Limited public data available on his specific firm affiliation, investment stage focus, and sector specialization
Investment thesis
Leads venture debt and equity investments in closely held and venture-backed companies, with a focus on bioscience and early-stage innovation
Kevin Crowley leads Connecticut Innovations' venture debt and equity investment portfolio, focusing on closely held and venture-backed companies with emphasis on bioscience and early-stage innovation. He deploys capital across multiple stages from pre-seed convertible instruments through later-stage venture rounds, with a track record spanning nearly two decades. The fund supports the Connecticut innovation ecosystem through direct investments, specialized facilities (wet lab infrastructure), incubator programs, and sector-specific initiatives like the UConn Innovation Fund and Connecticut Stem Cell Fund
Investment philosophy
Kevin Crowley leads Connecticut Innovations' Venture Debt portfolio, making loans to both closely held companies and venture-backed entities. Since joining in 2006, he has led investments in numerous companies that achieved IPOs or acquisitions, including Cara Therapeutics, Veradermics, HistoRx, Precipio Diagnostics, Solais Lighting, BioWave, Budderfly, ThayerMahan, Athletic Brewing, Q30, Enko, and Perosphere. He is a founding member of the UConn Innovation Fund, which invests in UConn-related technologies, and previously managed CI's $46 million BioFacilities Fund that supported the buildout of over 300,000 square feet of laboratory space in Connecticut. He also managed incubator laboratories and CI's pre-seed program for very early-stage companies.
Recent activity
Live platform data · proprietary, citable layer
Notable portfolio
Cara Therapeutics
Veradermics
HistoRx
Precipio Diagnostics
Solais Lighting
BioWave
Budderfly
ThayerMahan
Athletic Brewing
Q30
Enko
Perosphere
Frequently asked
Does Kevin Crowley invest at pre-seed stage?
Yes. They invest at pre-seed, seed, Series A stage.
Their geographic focus includes Connecticut.
What is their typical check size?
Check size is not publicly disclosed. They currently invest through Connecticut Innovations.
What sectors does Kevin Crowley focus on?
Kevin Crowley primarily invests in Bioscience, Life Sciences, Healthcare, bioscience.
Similar Bioscience investors
Sign up for free to unlock similar investors
Are you a fit for Kevin Crowley?
See your match score free · under a minute